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Abstract
Background: DNMT3A mutations are frequently discovered in acute myeloid leukemia (AML), associated with poor
outcome. Recently, a relapse case report of AML extramedullary disease has showed that AML cells harboring
DNMT3A variation were detected in the cerebral spinal fluid. However, whether a causal relationship exists between
DNMT3A mutation (D3Amut) and extramedullary infiltration (EMI) is unclear.
Methods: We took advantage of DNMT3A (R882C) mutation-carrying AML cell strain, that is, OCI-AML3, assessing its
migration ability in vitro and in vivo. By RNA interfering technology and a xenograft mouse model, we evaluated
the effect of DNMT3A mutation on cell mobility and explored the possible mechanism.
Results: OCI-AML3 displayed extraordinary migration ability in vitro and infiltrated into meninges of NOD/SCID
mice after intravenous transfusion. We found that this leukemic migration or infiltration capacity was significantly
compromised by the knockdown of DNMT3A mutant. Notably, TWIST1, a critical inducer of epithelial–mesenchymal
transition, which underlies the metastasis of carcinomas, was highly expressed in association with R882 mutations.
Abrogation of TWIST1 in DNMT3A mutated cells considerably weakened their mobility or infiltration.
Conclusions: Our results demonstrate that D3Amut in OCI-AML3 strain enhances leukemic aggressiveness by
promoting EMI process, which is partially through upregulating TWIST1.
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Background
Acute myeloid leukemia (AML) is a group of subtypes
that share common features with various manifestations.
Extramedullary infiltration (EMI) is a specific symptom of
bone marrow diseases, such as myeloid sarcoma, leukemia
cutis, and central nervous system (CNS) leukemia. The
prognosis of extramedullary event is controversial but
generally considered an advanced malignancy and indica-
tor of poor outcome [1, 2]. The mortality rate caused by
EMI, to some extent, is reduced by the means of standard
systemic chemotherapy combined with local treatment,
such as intrathecal injection and skin radiation [3].
However, extramedullary relapse after chemotherapy, even
hematopoietic stem cell transplantation, is still common
[4, 5].
Several lines of clinical analyses demonstrated that
the patients with abnormal karyotypes, such as t (8;
21), inv (16), and 11q23 translocations, tend to have
extramedullary diseases [1]. With regard to immuno-
phenotype, CD56-positive leukemic cells are prone to
infiltrate [6]. Additionally, a family of matrix metallo-
proteinases (MMPs) is considered to facilitate cell inva-
sion into soft tissues and CNS [7–9]. This evidence
confirms that molecular markers are useful to predict
leukemic progressive invasiveness.
Recently, a case report on an AML-M2 patient
relapsed with CNS leukemia after achieving complete
remission (CR) has attracted attention. Although no
DNMT3A mutation (D3Amut) is detected in the bone
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marrow and her buccal mucosal cells at diagnosis, dele-
tion of exon 18 in DNMT3A is observed in the cerebral
spinal fluid (CSF) on relapse stage [10]. However, the
mechanism on how the chemo-resistant subclone with
D3Amut could emerge in CNS remains unknown.
Mutated DNMT3A is highly relevant to higher WBC
counts, older age, and shorter survival in AML with muta-
tions compared with those with wild-type (WT) DNMT3A
[11, 12]. Mutated DNMT3A occurs in hematopoietic stem
cells and is considered a driver mutation in initiating
leukemia [13]. D3Amut is relatively obstinate. It can persist
in cases with morphologically CR [14] and be closely
associated with disease relapse or progression [15, 16].
Interestingly, this mutation has been frequently identified
in myelomonocytic and monoblastic phenotypes of AML
(AML-M4/M5) [11]. With these two subtypes, patients are
more likely to have EMI presentation [2, 17]. Nevertheless,
whether D3Amut takes part in EMI process is unclear.
In the present study, D3Amut could promote cell mi-
gration. OCI-AML3, a leukemia cell line harboring the
hotspot DNMT3A R882C mutation [18], could prolifer-
ate in NOD/SCID mice and induce paralysis and finally
death. Paralysis symptom was mentioned in a previous
study [19]. Our investigation demonstrated that this
particular symptom is caused by murine CNS leukemia,
which could be attributed to the cells bearing D3Amut.
Intriguingly, an epithelial–mesenchymal transition (EMT)
inducer, TWIST1, is activated upon D3Amut and could
facilitate aberrant leukemic cell migration.
Methods
Leukemic cell lines
Human AML cell lines (OCI-AML3, Kasumi-1, NB4,
THP-1, and U937) were all suspended and cultured in
RPMI-1640 medium (Invitrogen, Grand Island, USA) with
10 % FBS (Invitrogen, Grand Island, USA). OCI-AML3
strain was kindly provided by Dr. Lan Wang (Shanghai
Institutes for Biological Sciences, China). The four other
cell lines were obtained from Shanghai Institute of
Hematology. Logarithmically growing cells were used for
the experiments.
Primary AML blasts
Total bone marrow cells were collected from diagnosed
AML patients. These fresh cells were immediately
purified via density gradient centrifugation using Ficoll.
Leukemia blasts were harvested in the mononuclear
layer for experiments or storage. All patients provided
written informed consent for the use of their AML
samples under a protocol approved by the ethics
committee of Shanghai Institute of Hematology. Human
primary AML samples were obtained in accordance with
the ethical guidelines established by Shanghai Institute of
Hematology.
AML mouse model
Human AML cell strains OCI-AML3, U937, and THP-1
with or without exogenous plasmids transduction were
prepared in about (1–10) × 106 number. Cells were
injected into lethally irradiated 8-week-old NOD/SCID
mice through tail veins. Around 1 month post xenograft-
ing or at the time of paralysis, leukemic cells in murine
peripheral blood, bone marrow, spleen, or brain were
examined. All animal experiments were carried out in
accordance with the approved guidelines provided by
the Laboratory Animal Resource Center of Shanghai Jiao
Tong University School of Medicine.
RNA interference
The procedures of siRNA transfection and lentivirus-
mediated shRNA infection were described previously
[20]. The sequences of DNMT3A siRNA oligomers and
shRNA primers were according to previous study [20].


















cDNA templates were prepared after RNA extraction and
reverse transcription. Amplification was performed on a
real-time PCR system (Applied Biosystems 7500, USA).
The whole procedure was according to the manual of
SYBR® Premix Ex Taq™ kit (Takara RR420A, Japan). Relative
expression was calculated using the formula of 1/2△△Ct.
Transwell assay
Transwell® Permeable Supports (Costar 3421, Corning,
USA) was prepared to test cell migration. The assay was
carried out following the protocol provided by the
manufacturer.
Scratch-wound assay
About 6-cm diameter dish (Falcon, Bedford, USA) was
fully grown with adherent cells, and DMEM (Invitrogen,
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Grand Island, USA) medium with 10 % FBS was replaced
with pure DMEM medium. Cells were starved for 16 h in
an incubator at 37 °C and 5 % CO2. Subsequently, the
monolayer cells in the middle of the dish were scratched
using a sterile tip, and the dish was continuously
incubated for 12 h. Finally, cell number in the wound was
observed using a microscope (Nikon, TS100, NY, USA).
Flow cytometry and cell sorting
Immunophenotyping assays were all analyzed on LSRII
Flow Cytometer (Franklin Lakes, NJ, USA). Flow data were
further analyzed by FlowJo software (TreeStar, Ashland,
OR, USA). Antibodies were as follows: human CD44-APC
and human CD45-PE (BD Pharmingen™, NJ, USA).
Leukemic cells carrying green fluorescence proteins (GFPs)
or red fluorescence proteins were detected and selected by
MoFlo flow-sorter (Beckman coulter, Fullerton, CA, USA).
Western blotting
SDS-PAGE gels were prepared depending on protein size.
Electrophoresis and transmembrane were carried out on a
protein electrophoresis and blotting system (Bio-Rad,
Hercules, CA, USA). The signals were visualized using a
chemiluminescence detector (LAS-4000, FUJIFILM). The
antibodies used in this study were DNMT3A, SNAIL,
Flag, GAPDH (Cell Signaling, Danvers, USA), TWIST1,
VIMENTIN (Santa Cruz, Santa Cruz, USA), and β-actin
(Sigma, St. Louis, MO, USA).
Morphological analysis
Bone marrow cytospins and sections were subject to
Wright–Giemsa staining for morphological analyses.
Leukemic cells with Wright–Giemsa staining are large
and with round shape, pale blue cytoplasm, and pink
nucleus.
Immunohistochemical staining and immunofluorescence
Murine brain sections and spinal cord slices were pre-
pared for HE staining and human CD44 (Santa Cruz)
immunohistochemical staining. Exogenous cells labeled
by hCD44 in CNS were surrounded with brownish red
color. Murine brain or BM slices were observed under
Leica TCS SP8 confocal microscope (Leica Microsys-
tems, Wetzlar, Germany) after incubation with GFP (Cell
Signaling) or human CD44 antibody.
PET-CT
Around 1 month post xenografting, paralyzed mice
transplanted with OCI-AML3 strains were used for
PET-CT scanning (Siemense, Inveon PET-CT, USA)
after injecting fluorodeoxyglucose into mice bodies via
tail veins. Except for the brain, heart, and bladder, the
sites presented in highlight indicated a concentration of
leukemic cells caused by their active metabolism.
Bioluminescence imaging
Human AML cells carrying luciferase reporter were
transplanted into NOD/SCID mice. Luciferase substrate
was injected into living animals before imaging. In vivo
imaging system (Xenogen IVIS Spectrum, PerkinElmer)
was used for catching the fluorescence from the whole
body.
Results
DNMT3A R882 mutation enhances cell migration in vitro
We collected five AML cell lines (OCI-AML3, THP-1,
Kasumi-1, U937, and NB4) to examine their migration
capacity by using transwell assay. After 18 h of incuba-
tion, the number of migrated cells of OCI-AML3 was
higher than those of four other cell lines (p < 0.001)
(Fig. 1a). OCI-AML3 cells harbor D3Amut and NPM1
abnormality. NPM1 mutation is considered a marker for
relatively good prognosis, whereas D3Amut is associated
with poor outcome. Therefore, we focused on the possi-
bility of enhanced invasion of malignant cells rendered
by DNMT3A R882 mutation, which is an established
poor prognosis indicator. The protein level of DNMT3A
in OCI-AML3 was not the highest among the five cell
lines investigated (Additional file 1: Figure S1a). Subse-
quently, all exons of DNMT3A gene were sequenced in
the five lines, and the results showed the existence of
D3Amut only in OCI-AML3 (Additional file 1: Figure
S1b). We further constructed two DNMT3A knockdown
sublines of OCI-AML3 via specific siRNAs. The silence
of DNMT3A could dramatically reduce the capacity of
cell migration compared with control siRNA (p < 0.001)
(Fig. 1b). To rule out the effect caused by WT DNMT3A,
DNMT3A mRNA was downregulated in U937 cell line,
which was derived from a monocytic leukemia case with-
out D3Amut (Additional file 1: Figure S1b and S1c).
Transwell assay showed that, with WT DNMT3A de-
creasing, migration capacity of U937 was not significantly
altered (Additional file 1: Figure S1c).
To further assess the effect of D3Amut on cell migra-
tion, we overexpressed the WT and mutant DNMT3A
in U937, which exhibited low migration capacity
(Fig. 1a, c). Repeated independent transwell assays
showed that the numbers of migrated U937 cells stably
expressing DNMT3A R882C were higher than those
without D3Amut (p < 0.001) (Fig. 1c). In addition to
leukemia cells in suspension culture, the effect of
D3Amut on migration behavior in adherent cells was
also investigated. To eliminate the possible effect of en-
dogenous DNMT3A protein, we tested a series of solid
tumor cell lines and found little DNMT3A expression
in MDA-MB-231, a breast cancer cell line (Additional
file 1: Figure S1d). Scratch-wound experiment was
conducted, and cell motility was efficiently increased in
MDA-MB-231 cells expressing D3Amut but not in
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those expressing WT DNMT3A (Fig. 1d). Taken together,
these data suggest that DNMT3A R882 mutation contrib-
utes to enhance the migration of malignant cells.
EMI of OCI-AML3 cells in mice
To evaluate the migration capacity of OCI-AML3 cell
line in vivo, we transplanted OCI-AML3 cells into semi-
lethally irradiated NOD/SCID mice through tail veins.
Different quantities of OCI-AML3 cells, namely, 1 × 106,
5 × 106, and 1 × 107 cells, were inoculated into mice.
Around 20 days after xenografting, 36 of 37 animals
investigated developed weakness in hind limbs and walk-
ing in unequal steps, with the symptoms appearing the
earliest in mice inoculated with 1 × 107 cells, followed by
those with 5 × 106 and 1 × 106 cells (Fig. 2a). X-ray
examination eliminated the possibility of pathological
bone fracture in their hind limbs (Additional file 1:
Figure S2a). Mice were executed when they became
moribund. The average survivals in the three groups
challenged with OCI-AML3 cells were 20.6, 23.9, and
30.0 days (p < 0.001 compared with the controls)
(Additional file 1: Figure S2b). Mild splenomegaly was
observed in sick mice. Immunophenotypic staining of
human leukocyte-specific antigens hCD45 and hCD44
revealed the presence of OCI-AML3 cells in spleens
(Additional file 1: Figure S2c), and the percentage of
Fig. 1 DNMT3A R882 mutation enhances cell migration in vitro. a Transwell assays of acute leukemia cell lines OCI-AML3, THP-1, Kasumi-1, U937,
and NB4. Each strain is seeded in a number of 1 × 104 cells. Data are expressed as mean ± SD; n = 6 per group. b Transwell assays of OCI-AML3
with or without DNMT3A mRNA knockdown. About 1 × 104 of cells are purified for inoculation. Expression levels of DNMT3A proteins are shown
in the left panel. Data are presented as mean ± SD for each group (n = 7). c Transwell assays of U937 cells that are stably transfected by lentivirus
with wild-type (WT) DNMT3A or DNMT3A R882C. Overexpressed WT and mutant DNMT3A are indicated by Flag antibody in the upper panel.
Approximately 1 × 104 of purified cells is used for plating in each well. Data are expressed as mean ± SD (n = 6 per group). d Scratch-wound
assays of MDA-MB-231 cells stably expressing the vector of WT DNMT3A or DNMT3A R882C tagged by Flag. Upper panel shows the exogenous
DNMT3A expression by anti-Flag. Representative images in lower panel are shown at 0 and 12 h after scratching
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exogenous leukemia cells in the bone marrow (BM) was
relatively low (Additional file 1: Figure S2c).
To explore the cause of paralysis presentation, we
proposed the possibility of CNS abnormality caused by
extramedullary leukemia. Positron emission tomography-
computed tomography (PET-CT) was performed to inves-
tigate the hypermetabolic regions that are suggestive of
tumor infiltration. Compared with those of normal
controls, the spinal cords of sick mice contained more
radioactive substances (Fig. 2b), supporting the infiltration
of OCI-AML3 cells into CNS. To detect the disease status
at the entire organism level, we transfected luciferase
reporter lentivirus vector into OCI-AML3 cells and
subsequently transplanted the cells into the mice. All
transplanted animals developed a paralysis syndrome at
1 month post xenografting. Xenografts were observed
to infiltrate the brains, spinal cords, and BMs by using
bioluminescent imaging (Fig. 2c). Flow cytometry
showed quite a lot of xenografted cells in the brain
when hCD44 antigens were labeled (Fig. 2d). To exam-
ine whether other leukemia cell lines could cause CNS
infiltration, we used 5 × 106 cells of U937 and THP-1
lines, both from acute monocytic leukemia patients, for
transplantation. Around 20 days post xenografting,
U937 cell-transplanted mice developed severe leukemia,
but few exogenous cells were detected in the brain
(Fig. 2d). In THP-1 cell-transplanted mice, no leukemia
infiltration was observed in cerebral tissues at 40 days
post xenografting when the mice became moribund
(Fig. 2d). The above phenomenon demonstrates that
Fig. 2 Extramedullary infiltration of OCI-AML3 cells in mice. a Representative NOD/SCID mouse transplanted with OCI-AML3 cell line presents
paralysis syndrome at 1 month post xenografting. Red arrows indicate the paralyzed hind limbs. b PET and CT images show leukemia cells
infiltration in murine spinal cords. Radioactive substrates distributed in bladders are shown as the internal controls. c Bioluminescent imaging of NOD/
SCID mice at 1 month post xenografting. OCI-AML3 cells with luciferase are distributed mainly in the brain, spinal cord, and BM. d Representative FACS
plots of digested cells from control and OCI-AML3-, U937-, and THP-1-xenografted murine brains, where human CD44-positive (hCD44+) human
sources cells are gated to indicate
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OCI-AML3 cells could infiltrate into murine CNS and
induce characteristic clinical symptoms.
CNS-infiltrating leukemic cells concentrate in murine
meninges
Histopathologic examinations were carried out to
further verify the CNS-infiltrating characteristics. In sick
mice tissues, myeloid leukemia cells with large and
round shape, pale cytoplasm, and poly or band form
nucleus were accumulated in the brain meninges (Fig. 3a)
and spinal cord meninges (Fig. 3b). Immunohistochem-
istry results showed that these cells were also positive
for hCD44 (Fig. 3c). When mice transplanted with GFP
vector-containing OCI-AML3 cells were examined,
GFP-positive cells were shown along the brain meninges
(Fig. 3d). HE staining and immunofluorescence showed
the presence of around 10 % of exogenous leukemia cells
in murine BMs (Additional file 1: Figure S3a and S3b).
In addition, the genetic lesions of R882 loci were
detected to validate the exogenous cells. Targeted
sequencing results showed that GFP-positive samples
from BMs and brains all harbored R882C mutation,
which was the same as the control cells (Additional file
1: Figure S3c). Thus, OCI-AML3 cells are verified to
invade the brain and spinal cord meninges and induce
CNS leukemia.
Fig. 3 CNS-infiltrating leukemic cells concentrate in murine meninges. a HE staining of brain biopsies taken from control or transplanted mice.
Meningeal spaces are boxed in black. Myeloid cells infiltrate into brain meninges of OCI-AML3 group. b HE staining of spinal cord biopsies from
control or transplanted mice. Enlarged black boxes represent spinal meninges. Xenografts distributed along the spinal meninges are detected in
transplanted mice. c Immunohistochemical staining of murine brain and spinal cord. hCD44+ cells in brown, pointed by red arrows, indicate the
OCI-AML3 cells in transplanted mice. Black triangles and squares denote cerebral parenchymas and spinal cavities, respectively. Dashed lines
indicate the meninges. d Immunofluorescence shows murine brain meninges infiltrated by OCI-AML3 labeled by GFP antibody
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Abrogation of D3Amut exerts an anti-infiltration effect
Leukemic CNS infiltration indicates poor clinical
outcome. In this study, mice with a large number of
leukemia cells that infiltrated the meninges tended to
have worse general status. OCI-AML3 cells could infil-
trate into CNS in vivo, and D3Amut could promote cell
migration in vitro; hence, we speculated that inhibition
of heterozygous D3Amut in OCI-AML3 cells could
affect the ability of leukemic cell migration in mice. A
non-targeting control shRNA (sh-CTL) and two
shRNAs targeting DNMT3A (sh-DNMT3A-1 and 2)
were stably transfected into OCI-AML3. In these two
knockdown strains, cells with sh-DNMT3A-2 were col-
lected for transplantation because the expression of
DNMT3A was more reduced than that in other strain
(Additional file 1: Figure S4). Thus, OCI-AML3 cells
with sh-CTL and sh-DNMT3A-2 were purified in a
number of 1 × 106 cells for xenograft in NOD/SCID
mice. A luciferase reporter lentivirus vector was subse-
quently brought into OCI-AML3-sh-CTL (shControl)
and OCI-AML3-sh-DNMT3A-2 (shDNMT3A) cells.
With the same numbers of transplanted cells, the mo-
tility of OCI-AML3 with reduced D3Amut was largely
decreased in the brains and spinal cords of mice at
1 month post xenografting (Fig. 4a). Notably, mice in-
oculated with shDNMT3A cells had prolonged life
spans than those with shControl cells (p < 0.001)
(Fig. 4b). With regard to the mortality in the shControl
group, the contamination of a small number of OCI-
AML3 cells without DNMT3A knock down might com-
pete against shDNMT3A to cause late leukemic explosion.
These data show that abrogation of D3Amut could exert
an anti-infiltration effect and reduce the invasiveness of
leukemic cells.
TWIST1 represents a downstream target of D3Amut
To obtain insight into how D3Amut caused aberrant cell
migration of OCI-AML3, we analyzed a group of EMT
markers in OCI-AML3 strain. EMT-associated genes
promote cancer cell plasticity and tumor metastatic
spread, and the process can be induced by some factors,
such as TWIST1 and SNAIL [21]. We observed that
Fig. 4 Abrogation of D3Amut exerts an anti-infiltration effect. a Quantitative luciferase bioluminescence is monitored at day 30 post xenografting.
Values are as mean ± SEM (n = 6 per group). Representative bioluminescent image of mice transplanted with OCI-AML3 cells stably expressing
control shRNA (shControl) or shRNA-targeting DNMT3A (shDNMT3A). b Kaplan-Meier analysis shows the survival rates of mice receiving OCI-AML3
cells stably expressing a non-targeting shControl or an shDNMT3A
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OCI-AML3 cells harbored high expression levels of
TWIST1, SNAIL, and VIMENTIN. In other leukemia
cell lines, these EMT markers were relatively in lower
expressions except TWIST1 also highly expressing in
THP-1 (Fig. 5a). These markers in CNS-infiltrating
leukemia cells were further analyzed after cell sorting via
GFP-tag (Additional file 1: Figure S5a). TWIST1, the
most important transcriptional factor of EMT process,
was highly expressed in the brain tissues compared with
that in BMs (Fig. 5b). Subsequently, a series of AML
patients’ primary BM samples that harbor DNMT3A
R882H was analyzed. Interestingly, the mRNA and
protein levels of TWIST1 were higher in mutant cases
compared with those of DNMT3A WT ones (Figs. 5c,
d). Immunofluorescence also showed that TWIST1 was
highly expressed in primary leukemic cells with D3Amut
(Additional file 1: Figure S5b). In the meanwhile,
TWIST1 protein level was increased in U937 or MDA-
MB-231 strain by overexpression of D3Amut but not
WT DNMT3A (Additional file 1: Figure S5c). Also in
Kasumi-1 cells, the expressional levels of TWIST1 were
not changed after WT DNMT3A silencing so as to fur-
ther exclude the possible effect made by WT DNMT3A
(Additional file 1: Figure S5d). To evaluate the effect of
D3Amut on the expression of TWIST1, OCI-AML3
cells stably transfected with sh-DNMT3A lentivirus
displayed reduced TWIST1 with silenced D3Amut
(Additional file 1: Figure S4). The OCI-AML3 cells in
the brain had migrating capacity; thus, DNMT3A R882C
was knocked down in those cells to determine whether
phenotypes could be converted. The results showed that
TWIST1 expression and cell migration were both
reduced in brain-infiltrating cells (Fig. 5e). TWIST1
plays a key role during EMT. Therefore, we next transi-
ently transfected two siRNAs targeting TWIST1 mRNA in
brain-infiltrating cells. With decreasing TWIST1 level,
DNMT3A remained in abundance, whereas the migration
ability of brain-infiltrating cells was significantly reduced
Fig. 5 TWIST1 represents a downstream target of D3Amut. a Western blot of DNMT3A and EMT markers in acute leukemia cell lines OCI-AML3,
THP-1, Kasumi-1, U937, and NB4. b Western blot presents the EMT markers in GFP-positive OCI-AML3 strains and those sorted from murine BMs
and brains via GFP tags. c Real-time PCR of the mRNA levels of TWIST1 in AML patients’ primary BM cells with DNMT3A WT and DNMT3A R882H
mutations. Bar graphs show the mean ± SD of ten and eight cases in WT and mutant groups, respectively. d Western blot shows the DNMT3A
and TWIST1 in AML patients’ primary BM cells with DNMT3A WT and DNMT3A R882H mutations. e Left panel shows the Western blot analysis of
TWIST1 and DNMT3A in sorted OCI-AML3 cells located in murine brain. Those cells are transiently transfected by scramble siRNA (si-CTL) or two
different siRNAs targeting DNMT3A mRNA (si-DNMT3A-1 and 2). Transwell assays of OCI-AML3 cells from murine brain with or without DNMT3A
mRNA knocked down are shown in the right panel. About 200 purified cells are used for plating in one well. Data are presented as mean ± SD for
each group (n = 4). f Western blot of DNMT3A and TWIST1 in OCI-AML3 cells sorted from murine brain and are transiently transfected by si-CTL
or siRNAs targeting TWIST1 mRNA (si-TWIST1 and si-TWIST2). Transwell assays of those sorted cells with si-CTL, si-TWIST1, or si-TWIST2. Cells are
seeded in a number of 1 × 104. Data are expressed as mean ± SD (n = 6 per group)
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(Fig. 5f). This observation indicates that TWIST1 is prob-
ably a downstream of DNMT3A and could be involved in
the regulation of leukemia cell mobility process.
TWIST1 mediates enhanced cell migration ability in vivo
The role of TWIST1 on the migration ability of leukemic
cells in vivo was investigated. Two shRNAs (sh-TWIST1-
1 and 2) targeting TWIST1 mRNA were stably transfected
into OCI-AML3 cells by lentiviruses. Western blot ana-
lysis showed that both shRNAs successfully decreased
TWIST1 expressions, and the knockdown effect was more
remarkable in cells with sh-TWIST1-1 compared with
shControl and sh-TWIST1-2 (Additional file 1: Figure
S6a). Transwell assay also revealed that migrated cells
were reduced after TWIST1 knockdown, particularly by
sh-TWIST1-1 interference (Additional file 1: Figure S6b).
Thus, we used sh-TWIST1-1 for further study. Exogenous
leukemic cells with or without stable TWIST1 knockdown
(shTWIST1 or shControl) were sorted through GFP tags
and transplanted into NOD/SCID mice at a same number
of 5 × 105. One month later, shControl mice gradually
showed paralysis symptom, but such phenotype was not
observed in the group of shTWIST1 mice. Bioluminescent
imaging showed that in addition to BMs, exogenous grafts
in control mice were also distributed in the brains and
spinal cords. However, the EMI of leukemic cells in
shTWIST1 mice was few in CNS regions (Fig. 6a). Flow
cytometry further revealed that hCD44-positive cells were
detected in BMs of both control and shTWIST1 mice.
Interestingly, the analysis of brain samples showed that
the control one carried quite a few leukemic cells, whereas
almost no xenograft was observed in shTWIST1 mice
(Fig. 6b). Similar to the data from immunophenotyping
assay, histopathologic examinations with HE staining also
showed that transplanted cells were obviously noted in
the marrow cavities and brain meninges in control mice.
By contrast, leukemic cells in the shTWIST1 group were
detected in BMs but not in the brain meninges (Fig. 6c).
Immunohistochemistry confirmed few hCD44-positive
cells infiltrated in the brains of shTWIST1 mice (Fig. 6d).
Overall survival analysis demonstrated that shTWIST1
mice had longer life spans than control ones (p = 0.0022)
(Fig. 6e). Additionally, all shTWIST1 mice were not para-
lyzed in their limbs even when they died because of
leukemia. The results above indicate that TWIST1 is re-
quired for meninges migration of OCI-AML3 cells in
mice, and TWIST1 abrogation could significantly reduce
CNS infiltration.
Discussion
Genetic alterations are now regarded as important bio-
markers for disease evaluation and prognosis assessment.
In addition to chromosomal disorders, growing mutation
information is recognized in EMI procedure. Some case
reports found FLT3-ITD and NPM1 variations in myeloid
sarcomas with high frequencies of 15 and 14.4 %,
respectively. Extramedullary tumors that carry these two
abnormalities are mostly accompanied with cytogeneti-
cally normal AML and represent short lifespan, although
NPM1 mutation is considered a good prognostic indicator
[22, 23]. This observation demonstrates that genetic
mutation may independently affect disease progression in
systemic leukemia with EMI.
In the present study, genetic lesion located in exon 18 of
DNMT3A can promote leukemic cell migration. Meningeal
leukemia, where EMI is displayed, could be determined in
our NOD/SCID mice transplanted with human leukemic
cells carrying D3Amut. Hence, we provide a strong evi-
dence to support the clinical discovery of D3Amut in CSF
from CNS relapse patient [10]. Importantly, about 20 % of
our AML cases with D3Amuts and whose genetic profiles
have been reported before [24] showed CNS leukemia
when CSF was detected during disease courses.
D3Amuts are frequently detected in cases diagnosed
with M4 or M5 subtypes of AML [25]. D3Amut alone
could induce aggressive proliferation of differentiated
monocytes [20], thereby suggesting that this mutation
underlies the development of monocytic blasts [20]. MLL
abnormalities, which are mutually exclusive to D3Amuts
in M4/M5 variants [25], are related to extramedullary
disease [6]. Our results demonstrate that D3Amut, which
represents another group of AML patients with monocytic
involvement, might also be associated with EMI.
The role of DNMT3A in cell invasion has been
observed in lung cancer. Deletion of DNMT3A promotes
tumor progression and enables cells to invade into
bronchiole. Remarkably, a pool of genes in charge of cell
adhesion and motion is highly expressed in DNMT3A-
knockout mice [26]. Therefore, DNMT3A variation may
enhance tumor cell invasiveness through altering migrat-
ing mechanisms [26]. In our leukemic EMI model, an
EMT inducer TWIST1 is highly expressed in OCI-
AML3 strains and AML patients’ bone marrow samples
because of D3Amuts. EMT occurs in the initiation of
metastasis for cancer progression. It enables carcinoma
cells to escape cell-cell adhesion and gain migratory
phenotype. EMT involvement has been experimentally
proven in solid tumors [21]. Recently, a group from Italy
reported that EMT-like processes are relevant to acute
promyelocytic leukemia development or progression
[27]. This result implicates that EMT regulator TWIST1
causes leukemia invasive behavior. Our data further sug-
gest that the aggressive migratory behavior reminiscent
of TWIST1 also exists in extramedullary leukemia and
could be induced by DNMT3A R882 mutation.
DNMT3A is an epigenetic modifier, and mutation on
its catalytic domain can decrease enzymatic activities
and affect epigenetic modifications. We analyzed the
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Fig. 6 TWIST1 mediates enhanced cell migration ability in vivo. a Representative bioluminescent imaging of mice transplanted with OCI-AML3 cells
carrying luciferases and stably expressing scramble shRNA (shControl) or shRNA targeting TWIST1 (shTWIST1). Quantification of bioluminescent imaging
in brains and whole bodies is shown on the right panel. Values are presented as mean ± SEM (n = 6 per group). b Scatter plots present the OCI-AML3
cells with or without TWIST1 mRNA knockdown in murine BMs and brains, respectively. The percentage of exogenous cells is gated in blue
box. c HE staining of BM and brain biopsies taken from shControl or shTWIST1 mice. Black arrows indicate leukemic cells in marrow cavities or
brain meninges. d Immunohistochemical staining of hCD44+ cells indicated by red arrow in shControl murine brain. Black triangles denote
cerebral parenchymas. Dashed lines indicate the meninges. e Kaplan-Meier analysis shows the survival rates of shControl and shTWIST1 mice
(n = 6 per group)
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methylation level of TWIST1 genes in a set of primary
AML samples with normal karyotype from the TCGA
AML cohort [28]. This set includes 27 and 49 samples
with DNMT3A R882 mutations and WT DNMT3A,
respectively. Notably, in a region within 500-bp up-
and downstream of gene transcriptional start site, R882
mutation group showed hypomethylation (Additional
file 1: Figure S7). We suppose that D3Amut may lead
to the demethylation of TWIST1 gene, thereby increas-
ing its expression in leukemic cells. Interestingly, SHI-
1, a cell line harboring MLL-AF6 translocation derived
from an AML-M5 patient, can also invade murine
brain [29]. MLL is a histone modifying gene, and MLL
rearrangement interferes the normal function of MLL.
Therefore, EMI, as one of the features of AML-M4/M5
subtypes, may be partly attributed to epigenetic
deregulation.
EMI is one of the reasons for the relapsed and refractory
AML. Clinical studies have demonstrated that cells bearing
DNMT3A mutant are resistant to conventional chemother-
apy but sensitive to high-dose of daunorubicin-based
regimen [30, 31]. We suppose that dose-escalated therapy
might be useful for clearance of DNMT3A mutated cells,
thus disrupting cell mobility. Importantly, in our assays,
abrogation of DNMT3A mutant or TWIST1 in leukemic
cells reveals an anti-infiltration effect, thereby providing a
possible theoretical basis for clinical transformation.
Conclusions
In summary, our work first links D3Amut to leukemic cell
migration and demonstrate that D3Amut in OCI-AML3
strain enhances leukemic aggressiveness by promoting EMI
process, which is partially through upregulating TWIST1.
Therefore, AML patient with this variation should be given
further attention to the possibility of EMI, and D3Amut in
extramedullary tumor is worth to detecting in further study.
In addition, the inhibition of EMT inducer TWIST1 may
be potential therapeutic target of EMI in AML.
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